Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Blachly

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Protein Science : a Publication of the Protein Society|March 8, 2016
Structural characterization of NRAS isoform 5Joseph Markowitz, Tapas K Mal, Chunhua Yuan, et al.
Blood Advances|October 26, 2022
HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemiaTzung-Huei Lai, Hatice Gulcin Ozer, Pierluigi Gasparini, et al.
Investigational New Drugs|May 19, 2019
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLJae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, et al.
Bioinformatics (Oxford, England)|September 19, 2025
qcCHIP: an R package to identify clonal hematopoiesis variants using cohort-specific data characteristicsXiang Liu, Yi-Han Tang, James Blachly, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Experimental Hematology & Oncology|March 4, 2024
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signalingAlexander R Marr, Madeline Halpin, Dominique L Corbin, et al.
Blood|January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLLJennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Protein Science : a Publication of the Protein Society|March 8, 2016
Structural characterization of NRAS isoform 5Joseph Markowitz, Tapas K Mal, Chunhua Yuan, et al.
Blood Advances|October 26, 2022
HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemiaTzung-Huei Lai, Hatice Gulcin Ozer, Pierluigi Gasparini, et al.
Investigational New Drugs|May 19, 2019
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLJae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, et al.
Bioinformatics (Oxford, England)|September 19, 2025
qcCHIP: an R package to identify clonal hematopoiesis variants using cohort-specific data characteristicsXiang Liu, Yi-Han Tang, James Blachly, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Experimental Hematology & Oncology|March 4, 2024
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signalingAlexander R Marr, Madeline Halpin, Dominique L Corbin, et al.
Blood|January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLLJennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
Pageof 1